Date: 26 Sep 2012
- Greg L. Plosker
- … show all 1 hide
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Stiripentol is an anticonvulsant used as adjunctive therapy with valproate and clobazam in the management of patients with severe myoclonic epilepsy of infancy (SMEI; Dravet syndrome), a rare form of epilepsy that develops in the first year of life and is subsequently associated with significant morbidity and mortality. Results of a randomized, double-blind trial, in which patients (≥3 years of age) whose SMEI was inadequately controlled with valproate and clobazam received adjunctive therapy with stiripentol or placebo for 2 months, showed a significantly higher response rate in the stiripentol group compared with the placebo group (71 % vs. 5 %; p < 0.0001; primary endpoint). Responders were defined as those patients who experienced a ≥50 % reduction in clonic or tonic–clonic seizure frequency during the second month of the double-blind period compared with baseline. Almost half of the stiripentol recipients were seizure free during this period compared with none in the placebo group. Stiripentol was also statistically superior to placebo for secondary efficacy outcomes in the randomized controlled trial, which included the median number of seizures during the second month of the double-blind period and the mean percentage change from baseline in seizure frequency. These results are supported by efficacy data from other studies in patients with SMEI treated with stiripentol as adjunctive therapy, including a long-term retrospective analysis, prospectively conducted open-label studies and a meta-analysis. Drowsiness, loss of appetite and weight loss are the most frequently reported adverse events with stiripentol, and the drug inhibits various cytochrome P450 isoenzymes, potentially leading to clinically significant drug interactions. Stiripentol is an important addition to the limited treatment options available for the management of patients with SMEI.
The manuscript was reviewed by: Y. Inoue, Shizuoka Institute of Epilepsy and Neurological Disorders, Shizuoka, Japan; R. Nabbout, Service de Neurologie Pédiatrique, Hôpital Necker-Enfants Malades, Paris, France; and M. Sakauchi, Department of Pediatrics, Tokyo Women’s Medical University, Tokyo, Japan.
Stiripentol Chiron C. Neurotherapeutics. 2007;4(1):123–5.CrossRef
Diacomit® (stiripentol): EU summary of product characteristics. Gentilly: Biocodex, 2007 Jan 4.
Poisson M, Huguet F, Savattier A, et al. A new type of anticonvulsant, stiripentol: pharmacological profile and neurochemical study. Arzneimittelforschung. 1984;34(2):199–204.PubMed
Nabbout R, Chiron C. Stiripentol: an example of antiepileptic drug development in childhood epilepsies. Epub: Eur J Paediatr Neurol; 2012.
Grosenbaugh DK, Mott DD. Stiripentol is active in status epilepticus model [abstract]. Eleventh Eilat Conference on New Antiepileptic Drugs. Eilat; 2012 May 6–10.
Verleye M, Callizot N, Steinschneider R. Neuroprotective potential of stiripentol against oxygen and glucose deprivation or glutamate exposure in cultured rat cortical neurons [abstract]. Eleventh Eilat Conference on New Antiepileptic Drugs. Eilat; 2012 May 6–10.
Moreland TA, Astoin J, Lepage F, et al. The metabolic fate of stiripentol in man. Drug Metab Dispos. 1986;14(6):654–62.PubMed
Farwell JR, Anderson GD, Kerr BM, et al. Stiripentol in atypical absence seizures in children: an open trial. Epilepsia. 1993 Mar–Apr; 34 (2):305–11.
Volume 26, Issue 11 , pp 993-1001
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing AG
- Additional Links
- Industry Sectors
- Greg L. Plosker (1)
- Author Affiliations
- 1. Adis, 41 Centorian Drive, Mairangi Bay, North Shore 0754, Private Bag 65901, Auckland, New Zealand